Concepts (187)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electroencephalography | 39 | 2023 | 418 | 8.020 |
Why?
|
| Epilepsy | 18 | 2023 | 336 | 4.200 |
Why?
|
| Signal Processing, Computer-Assisted | 10 | 2022 | 100 | 3.910 |
Why?
|
| Neurophysiology | 12 | 2023 | 17 | 3.880 |
Why?
|
| Seizures | 17 | 2021 | 279 | 2.920 |
Why?
|
| Anticonvulsants | 12 | 2021 | 223 | 2.550 |
Why?
|
| Software | 8 | 2020 | 418 | 1.610 |
Why?
|
| Electromyography | 3 | 2021 | 184 | 1.460 |
Why?
|
| Brain Waves | 6 | 2018 | 30 | 1.160 |
Why?
|
| Lennox Gastaut Syndrome | 3 | 2021 | 3 | 1.140 |
Why?
|
| Brain | 8 | 2017 | 2176 | 1.090 |
Why?
|
| Epilepsies, Partial | 5 | 2022 | 24 | 0.930 |
Why?
|
| Diagnosis, Computer-Assisted | 3 | 2018 | 75 | 0.850 |
Why?
|
| Wavelet Analysis | 2 | 2013 | 5 | 0.840 |
Why?
|
| Epilepsy, Temporal Lobe | 5 | 2011 | 138 | 0.830 |
Why?
|
| Electrooculography | 1 | 2021 | 5 | 0.770 |
Why?
|
| Intensive Care Units | 4 | 2017 | 344 | 0.740 |
Why?
|
| Societies, Medical | 5 | 2016 | 403 | 0.740 |
Why?
|
| Humans | 64 | 2023 | 68618 | 0.730 |
Why?
|
| Polysomnography | 1 | 2021 | 92 | 0.730 |
Why?
|
| Observer Variation | 8 | 2020 | 330 | 0.720 |
Why?
|
| Carbamates | 4 | 2021 | 41 | 0.680 |
Why?
|
| Practice Guidelines as Topic | 4 | 2016 | 772 | 0.670 |
Why?
|
| Drug Resistant Epilepsy | 4 | 2021 | 44 | 0.660 |
Why?
|
| Artifacts | 2 | 2017 | 125 | 0.650 |
Why?
|
| Algorithms | 12 | 2020 | 1196 | 0.640 |
Why?
|
| Monitoring, Ambulatory | 2 | 2022 | 84 | 0.620 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2011 | 689 | 0.610 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 2017 | 9 | 0.610 |
Why?
|
| Electric Power Supplies | 1 | 2016 | 26 | 0.570 |
Why?
|
| Medical Informatics Applications | 1 | 2016 | 22 | 0.550 |
Why?
|
| Cannabidiol | 3 | 2021 | 31 | 0.540 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 848 | 0.540 |
Why?
|
| Hippocampus | 5 | 2011 | 471 | 0.530 |
Why?
|
| Video Recording | 3 | 2016 | 145 | 0.530 |
Why?
|
| Data Interpretation, Statistical | 1 | 2017 | 329 | 0.520 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2016 | 2223 | 0.510 |
Why?
|
| Atrophy | 5 | 2011 | 112 | 0.480 |
Why?
|
| Artificial Intelligence | 2 | 2013 | 159 | 0.470 |
Why?
|
| Scalp | 4 | 2020 | 47 | 0.440 |
Why?
|
| Electronic Health Records | 1 | 2016 | 374 | 0.410 |
Why?
|
| Epilepsies, Myoclonic | 2 | 2021 | 8 | 0.390 |
Why?
|
| Expert Systems | 1 | 2011 | 9 | 0.390 |
Why?
|
| Double-Blind Method | 7 | 2021 | 1738 | 0.370 |
Why?
|
| Implantable Neurostimulators | 2 | 2020 | 12 | 0.360 |
Why?
|
| Electrodes | 3 | 2016 | 147 | 0.360 |
Why?
|
| Adult | 22 | 2022 | 21403 | 0.360 |
Why?
|
| Afferent Pathways | 1 | 2010 | 31 | 0.350 |
Why?
|
| Drug Therapy, Combination | 5 | 2021 | 649 | 0.350 |
Why?
|
| Treatment Outcome | 12 | 2021 | 7029 | 0.340 |
Why?
|
| Temporal Lobe | 1 | 2010 | 125 | 0.330 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2010 | 239 | 0.310 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2010 | 211 | 0.310 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2010 | 333 | 0.310 |
Why?
|
| Female | 25 | 2020 | 38074 | 0.300 |
Why?
|
| Prospective Studies | 6 | 2021 | 3705 | 0.290 |
Why?
|
| Nerve Net | 1 | 2009 | 181 | 0.290 |
Why?
|
| Male | 22 | 2020 | 37321 | 0.290 |
Why?
|
| Electrocardiography | 1 | 2009 | 601 | 0.280 |
Why?
|
| Akathisia, Drug-Induced | 1 | 2006 | 4 | 0.270 |
Why?
|
| Retrospective Studies | 5 | 2020 | 7277 | 0.270 |
Why?
|
| Apolipoproteins E | 1 | 2006 | 92 | 0.260 |
Why?
|
| Pattern Recognition, Automated | 2 | 2018 | 70 | 0.260 |
Why?
|
| Epilepsy, Generalized | 2 | 2018 | 15 | 0.260 |
Why?
|
| Alleles | 1 | 2006 | 386 | 0.250 |
Why?
|
| Suicide | 2 | 2022 | 116 | 0.240 |
Why?
|
| Middle Aged | 15 | 2020 | 21147 | 0.230 |
Why?
|
| Chlorophenols | 2 | 2021 | 6 | 0.230 |
Why?
|
| Inpatients | 2 | 2021 | 208 | 0.220 |
Why?
|
| Sleep | 4 | 2023 | 263 | 0.220 |
Why?
|
| Tetrazoles | 2 | 2021 | 160 | 0.210 |
Why?
|
| Pick Disease of the Brain | 1 | 2002 | 4 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2006 | 786 | 0.210 |
Why?
|
| Depression, Postpartum | 1 | 2002 | 9 | 0.210 |
Why?
|
| Adolescent | 8 | 2020 | 8912 | 0.200 |
Why?
|
| Quality of Life | 2 | 2020 | 1515 | 0.200 |
Why?
|
| Databases, Factual | 2 | 2017 | 622 | 0.190 |
Why?
|
| Sensitivity and Specificity | 6 | 2020 | 1753 | 0.190 |
Why?
|
| Reference Standards | 1 | 2021 | 115 | 0.190 |
Why?
|
| Piperidines | 1 | 2021 | 123 | 0.180 |
Why?
|
| Deep Brain Stimulation | 1 | 2020 | 71 | 0.170 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2020 | 61 | 0.170 |
Why?
|
| Young Adult | 7 | 2020 | 5717 | 0.170 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 2077 | 0.170 |
Why?
|
| Pyridines | 1 | 2021 | 261 | 0.170 |
Why?
|
| Neurologists | 1 | 2018 | 15 | 0.160 |
Why?
|
| Hospitals, Private | 1 | 2018 | 15 | 0.160 |
Why?
|
| Electric Stimulation Therapy | 1 | 2020 | 147 | 0.160 |
Why?
|
| Phenytoin | 1 | 2018 | 27 | 0.160 |
Why?
|
| Depressive Disorder, Major | 1 | 2022 | 439 | 0.160 |
Why?
|
| Mental Disorders | 1 | 2003 | 659 | 0.150 |
Why?
|
| Reference Values | 2 | 2016 | 579 | 0.150 |
Why?
|
| Spectrum Analysis | 1 | 2016 | 81 | 0.140 |
Why?
|
| Child, Preschool | 3 | 2019 | 3187 | 0.140 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 281 | 0.140 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2016 | 137 | 0.140 |
Why?
|
| Drug Administration Schedule | 3 | 2015 | 567 | 0.130 |
Why?
|
| Outpatients | 1 | 2016 | 127 | 0.130 |
Why?
|
| Cerebral Cortex | 2 | 2010 | 415 | 0.130 |
Why?
|
| Carbamazepine | 1 | 2015 | 108 | 0.120 |
Why?
|
| Terminology as Topic | 1 | 2015 | 141 | 0.120 |
Why?
|
| ROC Curve | 2 | 2013 | 392 | 0.120 |
Why?
|
| Brain Mapping | 3 | 2016 | 532 | 0.120 |
Why?
|
| United States | 5 | 2016 | 7367 | 0.110 |
Why?
|
| User-Computer Interface | 2 | 2015 | 230 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 2279 | 0.110 |
Why?
|
| Memory | 1 | 2015 | 214 | 0.110 |
Why?
|
| Aged | 6 | 2020 | 14862 | 0.110 |
Why?
|
| Time Factors | 4 | 2016 | 4655 | 0.110 |
Why?
|
| Transcranial Direct Current Stimulation | 1 | 2015 | 111 | 0.110 |
Why?
|
| Sclerosis | 2 | 2010 | 32 | 0.110 |
Why?
|
| Critical Care | 1 | 2015 | 263 | 0.110 |
Why?
|
| Dominance, Cerebral | 2 | 2010 | 65 | 0.110 |
Why?
|
| Child | 3 | 2019 | 6405 | 0.100 |
Why?
|
| Databases as Topic | 1 | 2012 | 49 | 0.100 |
Why?
|
| Single-Blind Method | 3 | 2018 | 249 | 0.100 |
Why?
|
| Parahippocampal Gyrus | 1 | 2010 | 15 | 0.090 |
Why?
|
| Putamen | 1 | 2010 | 35 | 0.090 |
Why?
|
| Nerve Fibers | 1 | 2010 | 77 | 0.090 |
Why?
|
| Thalamus | 1 | 2010 | 82 | 0.090 |
Why?
|
| Limbic System | 1 | 2010 | 106 | 0.080 |
Why?
|
| Cerebellum | 1 | 2010 | 103 | 0.080 |
Why?
|
| Gyrus Cinguli | 1 | 2010 | 113 | 0.080 |
Why?
|
| Veterans | 1 | 2016 | 904 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 186 | 0.080 |
Why?
|
| Amygdala | 1 | 2010 | 159 | 0.080 |
Why?
|
| Internet | 1 | 2011 | 390 | 0.080 |
Why?
|
| Neural Pathways | 1 | 2009 | 324 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 1465 | 0.070 |
Why?
|
| Choristoma | 1 | 2006 | 20 | 0.070 |
Why?
|
| Recurrence | 1 | 2009 | 948 | 0.070 |
Why?
|
| Apolipoprotein E2 | 1 | 2006 | 8 | 0.070 |
Why?
|
| Brain Diseases | 1 | 2006 | 78 | 0.070 |
Why?
|
| Cross-Over Studies | 2 | 2018 | 260 | 0.070 |
Why?
|
| Gene Frequency | 1 | 2006 | 207 | 0.070 |
Why?
|
| Disease Progression | 1 | 2009 | 1038 | 0.060 |
Why?
|
| Risk | 1 | 2006 | 563 | 0.060 |
Why?
|
| Schizophrenia | 1 | 2006 | 206 | 0.060 |
Why?
|
| Magnetoencephalography | 1 | 2003 | 6 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 1851 | 0.060 |
Why?
|
| Magnetics | 1 | 2003 | 52 | 0.060 |
Why?
|
| Evoked Potentials | 1 | 2003 | 61 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2023 | 73 | 0.050 |
Why?
|
| Time | 1 | 2022 | 57 | 0.050 |
Why?
|
| Functional Laterality | 1 | 2003 | 240 | 0.050 |
Why?
|
| Natalizumab | 1 | 2021 | 6 | 0.050 |
Why?
|
| Epileptic Syndromes | 1 | 2021 | 3 | 0.050 |
Why?
|
| Suicidal Ideation | 1 | 2022 | 106 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2020 | 219 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2020 | 238 | 0.040 |
Why?
|
| Intracranial Hemorrhages | 1 | 2020 | 80 | 0.040 |
Why?
|
| Prosthesis-Related Infections | 1 | 2020 | 70 | 0.040 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 426 | 0.040 |
Why?
|
| Status Epilepticus | 1 | 2020 | 74 | 0.040 |
Why?
|
| Memory Disorders | 1 | 2020 | 111 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2002 | 1140 | 0.040 |
Why?
|
| Comorbidity | 1 | 2022 | 1426 | 0.040 |
Why?
|
| Glasgow Coma Scale | 1 | 2018 | 65 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 4848 | 0.040 |
Why?
|
| Multimodal Imaging | 1 | 2016 | 62 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2016 | 95 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2016 | 114 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 2020 | 621 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 931 | 0.030 |
Why?
|
| Equipment and Supplies | 1 | 2016 | 18 | 0.030 |
Why?
|
| Brain Abscess | 1 | 2015 | 7 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 306 | 0.030 |
Why?
|
| Automation | 1 | 2015 | 45 | 0.030 |
Why?
|
| Computer Graphics | 1 | 2015 | 37 | 0.030 |
Why?
|
| Association Learning | 1 | 2015 | 36 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2015 | 215 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2015 | 411 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 3259 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 148 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1054 | 0.030 |
Why?
|
| Risk Factors | 1 | 2022 | 5731 | 0.030 |
Why?
|
| Animals | 1 | 2009 | 20881 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2011 | 219 | 0.020 |
Why?
|
| Infant | 1 | 2016 | 2891 | 0.020 |
Why?
|
| Glucuronosyltransferase | 1 | 2009 | 38 | 0.020 |
Why?
|
| Dizziness | 1 | 2009 | 27 | 0.020 |
Why?
|
| Placebos | 1 | 2009 | 195 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 2358 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 1745 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2006 | 342 | 0.010 |
Why?
|
| Stroke | 1 | 2015 | 2163 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2006 | 1553 | 0.010 |
Why?
|